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Abstract This paper reviews our present knowledge of sphin-
gomyelinases as enzymes, and as enzymes acting on a mem-
brane constituent lipid, sphingomyelin. Six types of sphingomye-
linases are considered, namely acidic, secretory, Mg2+-de-
pendent neutral, Mg2+-independent neutral, alkaline, and bac-
terial enzymes with both phospholipase C and sphingomyelinase
activity. Sphingomyelinase assay methods and speci¢c inhibitors
are reviewed. Kinetic and mechanistic studies are summarized, a
kinetic model and a general-base catalytic mechanism are pro-
posed. Sphingomyelinase^membrane interactions are considered
from the point of view of the in£uence of lipids on the enzyme
activity. Moreover, e¡ects of sphingomyelinase activity on mem-
brane architecture (increased membrane permeability, mem-
brane aggregation and fusion) are described. Finally, a number
of open questions on the above topics are enunciated.
, 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction and scope
Sphingomyelinases are enzymes that catalyze the hydrolysis
of sphingomyelin (ceramide phosphorylcholine) into ceramide
and phosphorylcholine. The reaction is formally similar to
that of a phospholipase C. Sphingomyelinases have been
known for many years [1,2], but in the last decade they
have become the object of renewed interest after the discovery
of the sphingomyelin signal transduction pathway [3^6]. Cer-
amide appears to be a lipid second messenger in programmed
cell death (apoptosis), cell di¡erentiation and cell proliferation
(see reviews in [7^12]; but see also, for the opposite point of
view, [13]), and sphingomyelinase is probably a major source
of ceramide in the cells, although this is also a debated point.
In the midst of the advances, doubts, mistakes and correc-
tions that mark a living scienti¢c ¢eld, the last 12 years have
witnessed a turmoil in the area of sphingomyelinases ; known
enzymes have been re-examined in the light of new physiolog-
ical evidence, novel sphingomyelinases have been puri¢ed,
some have been cloned and overexpressed T and the storm
is far from dying down. Thus, the present review cannot be
but a provisional assessment of the state of the art in 2002.
We have chosen two main aspects of sphingomyelinases to
be covered in this review, one corresponds to the point of view
of ‘classical enzymology’, with a description of the known
sphingomyelinases, and of their properties. The second is
more directly related to our experimental work, and describes
the interaction of sphingomyelinases with phospholipid bi-
layers, and the mutual in£uence of enzyme and substrate
properties. One important function of sphingomyelinases
may be related to changing membrane properties (charge,
£uidity, permeability) by transforming sphingomyelin into
ceramide. The present work does not cover the cell physiolog-
ical e¡ects of sphingomyelinases, these are described in detail
in the above mentioned reviews.
2. Sphingomyelinases
2.1. Types of sphingomyelinases
Samet and Barenholz [14] proposed a useful classi¢cation of
sphingomyelinases into ¢ve categories. We shall follow rather
closely their description, adding a sixth group for a speci¢c
kind of bacterial sphingomyelinases.
2.1.1. Acid sphingomyelinase (aSMase). This soluble gly-
coprotein was the ¢rst described sphingomyelinase [1]. Its
name refers to the fact that its optimum activity is at pH
V5, as be¢ts its localization in lysosomes. It is number EC
3.1.4.12 in the Enzyme Commission classi¢cation. The ab-
sence of this enzyme is responsible for the neurological disor-
der known as Niemann^Pick syndrome. It is the best charac-
terized of the sphingomyelinases [14]. It has been cloned from
human DNA and expressed in Escherichia coli [15^17] and in
insect Sf21 cells [18,19]. In the latter case the recombinant
protein is secreted as a 72 kDa protein, as opposed to the
75 kDa molecule puri¢ed from human placenta, both proteins
having similar sphingomyelinase activity. Human aSMase has
also been overexpressed in Chinese hamster ovary cells [20],
and the authors have described the preparation and use of a
£uorescent FITC-labelled aSMase. Acid sphingomyelinases
have been recently characterized from leukemia HL-60 cells
[14], and thrombin-activated human platelets [21,22]. The lat-
ter enzyme (70^73 kDa) may not originate in the lysosomes
[22]. A 58 kDa aSMase has been located in the lesional skin of
atopic dermatitis patients [23].
Grassme et al. [24] described the overexpression of human
aSMase in JY B cells and in aSMase-de¢cient lymphocytes
from patients with Niemann^Pick disease type A. These au-
thors made the important observation that, upon activation of
the surface receptor Fas (CD95), a SMase was translocated
from its intracellular location to the plasma membrane outer
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lea£et, which is rich in sphingomyelin. aSMase activity in-
duced clustering of CD95 in sphingolipid-rich membrane
rafts, and subsequent apoptosis. Clustering was probably the
result of lateral segregation of ceramide (see Section 3.2). In a
related observation Cremesti et al. [25] showed that the anti-
Fas antibody-induced lateral segregation (‘capping’) of Fas
into one pole of the cell membrane was ceramide-dependent,
and that SMase3=3 hepatocytes were defective in antibody-
induced ceramide generation, capping and apoptosis.
2.1.2. Secretory sphingomyelinase (sSMase). This enzyme
arises from the acid sphingomyelinase gene via di¡erential
protein tra⁄cking of a common protein precursor; this pre-
cursor can be targeted either to lysosomes (aSMase) or to the
Golgi secretory pathway (sSMase) [26,27]. The secretory en-
zyme is typically activated by physiological concentrations of
Zn2þ, but Zn2þ-independent forms may exist [27]. sSMases
may be involved in signal transduction via the sphingomyelin
pathway. A review of sSMases can be found in [28].
Secretory sphingomyelinase has been proposed to have a
role in atherogenesis. It was known that serum low density
lipoprotein (LDL), when treated with bacterial sphingomyeli-
nase, gave rise to LDL aggregates that became retained on the
extracellular matrix and stimulated macrophage foam cell for-
mation [29]. Schissel et al. [26] were able to show that sSMase
from arterial wall cells could hydrolyze and aggregate LDL
modi¢ed by oxidation, or extracted from human atheroscle-
rotic lesions, at pH 7.4, while native LDL could only be
cleaved by sSMase at pH 5.5. Thus sSMase is likely to be
the arterial wall enzyme responsible for the hydrolysis of
sphingomyelin in LDL and subendothelial LDL aggregation,
a key event in atherogenesis. In addition, macrophages from
aSMase knockout mice, thus deprived of both aSMase and
sSMase, displayed defective cholesterol tra⁄cking and e¥ux
[30]. This may implicate sSMase de¢ciency as a new athero-
sclerosis risk factor.
2.1.3. Neutral, Mg2+-dependent sphingomyelinases (nSMase)
Neutral Mg2þ-dependent sphingomyelinases are integral
membrane proteins in mammals, and soluble proteins in bac-
teria. The mammalian enzymes have pH optima near 7, and
require millimolar concentrations of Mg2þ or Mn2þ for activ-
ity. nSMase appears to be ubiquitous in mammalian tissues,
but the highest activities occur in brain. The molecular mass is
about 92 kDa, although smaller isoenzymes are found, which
may result either from proteolysis or from alternative process-
ing of common transcripts. nSMase is activated, either di-
rectly or indirectly, by a number of molecules including oxi-
dized LDL and tumor necrosis factor-K (TNF-K), so that the
enzyme may be related, among others, to atherosclerosis and
apoptosis. A review of neutral sphingomyelinases, stressing
the physiological aspects, can be found in Chatterjee [31].
The ¢rst nSMases of mammalian origin were characterized
by Gatt [32] and by Rao and Spence [33]. Liu et al. [34]
puri¢ed by 3030-fold a Mg2þ-dependent, nSMase activity
(molecular mass ca. 60 kDa) from rat brain membranes. En-
zyme activity was highly dependent on phosphatidylserine,
and it was 95% inhibited by 3 mM glutathione [35]. Gluta-
thione inhibition suggested that nSMase was activated by
stress [36]. More recently, Bernardo et al. [37] puri¢ed by
23 330-fold a Mg2þ-dependent nSMase from bovine brain
that was inhibited by glutathione. The enzyme consisted of
two polypeptides, of 97 kDa and 46 kDa, that appeared to
be structurally related, the latter being probably a degradation
product. The bovine enzyme shares many properties with the
one puri¢ed by Liu et al. [34] from rat brain (Mg2þ depen-
dence, substrate speci¢city, activation by phosphatidylserine,
inhibition by glutathione). However, the respective molecular
masses were di¡erent, 60 vs. 97 kDa, thus the relationship
between both enzymes remains to be established.
Ghosh et al. [38] isolated two isoforms of nSMase from
rabbit skeletal muscle, of molecular masses 92 and 53 kDa
respectively. Peptide mapping revealed important structural
similarities, and the catalytic activities were also similar, ex-
cept that the 53 kDa protein was Mg2þ-independent. The
location of these nSMases is in the transverse tubules of the
muscle cells, which may be related to the observation that
sphingosine modulates calcium release from sarcoplasmic re-
ticulum membranes [39]. Two Mn2þ- and Mg2þ-dependent
nSMases located in the microsomal membranes of seminifer-
ous tubes of immature Wistar rats have been characterized
[40] whose properties do not appear to di¡er signi¢cantly
from other mammalian nSMases. To end this short reference
to nSMases puri¢ed from eukaryotic natural sources, we shall
mention the Mg2þ-dependent nSMase isolated from Saccha-
romyces cerevisiae [41], and the one obtained from membrane
fractions of intraerythrocytic Plasmodium falciparum, the ma-
laria parasite [42]. The latter enzyme was activated by phos-
phatidylserine and other anionic phospholipids, and was sen-
sitive to scyphostatin, an inhibitor of mammalian nSMase (see
below).
The cloning of mammalian nSMase has not been free from
debate. Tomiuk et al. [43] announced the cloning, overexpres-
sion and functional characterization of murine and human
Mg2þ-dependent nSMase. Cloning was achieved by searching
for sequences similar to those of bacterial nSMase. Overex-
pressing cells were treated with TNF-K but no clearly elevated
ceramide levels or apoptosis were observed, which argued
against the proposed role of nSMase in apoptosis. However,
several concerns were soon raised, particularly with respect to
the speci¢city of the cloned protein, i.e. it was not clear
whether sphingomyelin was the natural substrate or not.
Shortly afterwards Sawai et al. [44] demonstrated that
although the cloned nSMase had sphingomyelinase activity
in vitro, cells overexpressing the protein did not show marked
changes in sphingomyelin metabolism. Furthermore 1-O-al-
kyl-lyso-phosphatidylcholine (lyso-platelet activating factor,
or lyso-PAF) was metabolized into 1-O-alkylglycerol in over-
expressing cells, but not in vector cells. Sawai et al. [44] con-
cluded that the protein acted as lyso-PAF phospholipase C
rather than as nSMase in cells. More recently Neuberger et al.
[45] demonstrated the localization of the enzyme cloned by
Tomiuk et al. [43] in the endoplasmic reticulum of cells.
This location would argue against a role of this enzyme in
sphingomyelin signalling.
In a further paper Tomiuk et al. [46] also reached the con-
clusion that the enzyme they had previously cloned (nSMase 1
in their nomenclature) was predominantly localized in the
microsomal fraction (endoplasmic reticulum and Golgi). The
observation that anti-nSMase 1 antibodies did not a¡ect the
nSMase activity in membrane fractions from murine brain
[46] was interpreted as an indication that nSMase 1 was one
of at least two mammalian nSMases. In fact, shortly after-
wards the same group published the cloning and character-
ization of a 71 kDa mammalian brain-speci¢c, Mg2þ-depen-
dent nSMase [47], which they called nSMase 2. This enzyme
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colocalized with a Golgi marker in several cell lines, according
to immuno£uorescence methods.
The enzyme with lyso-PAF phospholipase C and nSMase
activities (nSMase 1) has been the object of attention by sev-
eral groups. Katan and co-workers con¢rmed its localization
in the endoplasmic reticulum, and showed that the enzyme
had a strong requirement for reducing agents, and was revers-
ibly inhibited by reactive oxygen species and by oxidized glu-
tathione [48]. The same laboratory reported an essential role
for two His residues (136 and 272 in nSMase 1) that were
conserved in sequences from bacteria to human, and demon-
strated that the transmembrane region contained determinants
for the endoplasmic reticulum localization [49]. Mizutani et al.
[50] cloned and expressed an essentially similar enzyme from
rat, which they located afterwards in the nuclear matrix of
ascites hepatoma AH7974 cells [51].
Meanwhile, Chatterjee et al. [52] had cloned a putative hu-
man nSMase that was activated by Mg2þ, inhibited by gluta-
thione, and used sphingomyelin as its preferred substrate. The
enzyme contained a ‘death domain’ analogous to those of
TNF-K receptor-1 and Fas/Apo-I, and had no homology
with the nSMase 1 from Tomiuk et al. [43]. The ‘Chatterjee
enzyme’ overexpressed in human aorta smooth muscle cells
stimulated apoptosis [52] while, as mentioned above, the ‘To-
miuk enzyme’ overexpressed in HEK cells or U937 cells did
not induce apoptosis in the presence of TNF-K [43]. But Ro-
drigues-Lima et al. [49] indicated that expression of the ‘Chat-
terjee enzyme’ resulted only in a small increase in hydrolysis
of exogenous sphingomyelin, and they even pointed out the
sequence similarity of that enzyme with isochorismate synthe-
tase. In addition, the ‘Chatterjee enzyme’ has not yet been
found in the human genome data bank. In summary, it is
not clear whether any of the putative nSMases cloned up to
now have a physiological role as a sphingomyelinase and it is
doubtful that any of them participate in the sphingomyelin
signalling pathway.
Sphingomyelin signalling in response to external agents
(TNF-K, oxidized LDL, T) evokes the existence of a SMase
at the plasma membrane level. It is thus disappointing that
none of the cloned nSMases is localized there. In contrast,
two recent reports characterize plasma membrane-associated
nSMases. Veldman et al. [53] described a nSMase in caveolae
of human skin ¢broblasts. This enzyme was inhibited by a
peptide that corresponded to the sca¡olding domain of cav-
eolin, which suggested a direct molecular interaction of both
proteins. Such interaction would in turn imply a cytosolic
orientation of the caveolar nSMase. Stimulation of overex-
pressing ¢broblasts with TNF-K resulted in the appearance
of caveolin-sensitive nSMase activity in the non-caveolar frac-
tions. These results suggest that caveolar nSMase may be in-
volved in TNF-K signalling. Working on a di¡erent system,
namely pig liver plasma membranes, Martin et al. [54] isolated
a Mg2þ-dependent nSMase that was not inhibited by gluta-
thione but was inhibited by ubiquinol and other lipophilic
antioxidants. Also relevant in this context is the somewhat
forgotten report of a latent nSMase in chicken erythrocyte
membranes [55].
A recent signi¢cant discovery has been the identi¢cation of
a nSMase activity in LDL [56,57]. These authors have dem-
onstrated that apolipoprotein B-100, the protein moiety of
LDL, has a nSMase activity, which is also re£ected by partial
sequence homology between apolipoprotein B-100 and bacte-
rial SMases. The physiological role of this activity could be
related to non-receptor-mediated endocytotic entry of LDL
into cells. Apart from that, this observation may open a
new mechanistic link between elevated plasma levels of
LDL, apoptosis and atherosclerosis.
A whole group of sphingomyelinases found in bacteria are
structurally related to nSMase 1 [43,49]. In this sense they can
be called neutral sphingomyelinases, although in practice they
show a rather wide range of pH optima, and hydrolyze phos-
pholipids other than sphingomyelin. These enzymes have been
found in Bacillus cereus, Staphylococcus aureus (L-toxin), Lis-
teria ivanovi, Leptospira interrogans, Chromobacterium viola-
ceum, Helicobacter pylori and Pseudomonas TK4 [58^62]. Of
these, the nSMase from B. cereus is the best known one. A
distant evolutionary relationship has been noted between bac-
terial sphingomyelinase and mammalian DNase I [63]. These
authors found that residues of DNase I that are involved in
the active center (including His 134 and His 252) are con-
served in bacterial sphingomyelinase, and are essential for
activity. They correspond to the essential His 136 and His
272 in nSMase 1 [49]. Bacterial sphingomyelinases may be
descendants of the eukaryotic enzymes, as proposed by Heinz
et al. [64] for certain phospholipases C. In favor of this hy-
pothesis is the fact that these enzymes are not usually required
for the bacterial life cycle, and are often found in pathogens
functioning as bacterial toxins [49]. The similarity between
bacterial and mammalian nSMases has made it possible to
subclone chimeras of bacterial SMase and green £uorescent
protein into mammalian vectors containing sequences that
target the enzyme to several subcellular organelles, with the
result that only when bacterial SMase was targeted to mito-
chondria did cells undergo apoptosis [65].
2.1.4. Mg2+-independent neutral sphingomyelinases. This
small and barely known group of sphingomyelinases includes
an enzyme found in the cytosol of HL-60 cells by Okazaki et
al. [66], and the 53 kDa isoform of nSMase found by Ghosh
et al. [38] in rabbit skeletal muscle.
2.1.5. Alkaline sphingomyelinase from the intestinal tract
The best characterized enzyme in this group has been an al-
kaline sphingomyelinase (bSMase), puri¢ed ca. 1600-fold
from rat intestine [67]. The enzyme is not expressed in other
organs, requires bile salts for activity, is Mg2þ-independent,
and not inhibited by glutathione. The lack of this enzyme may
be related to colon carcinogenesis. For a review, see Nilsson
and Duan [68].
2.1.6. Bacterial sphingomyelinase-phospholipase C. This
category was not included in the classi¢cation of Samet and
Barenholz [14]. At least two representatives are known of this
group, namely the so-called K-toxin from Clostridium perfrin-
gens [69], and the product of the plcB gene from Listeria
monocytogenes [70]. Both can use phosphatidylcholine and
sphingomyelin as substrates, and perhaps other glycerophos-
pholipids as well [71]. Both enzymes are structurally related
to the phosphatidylcholine-preferring phospholipase C from
B. cereus but the latter has no SMase activity.
2.2. Sphingomyelinase mechanism
2.2.1. Binding of magnesium ions. Activation by Mg2þ is
observed in most, but not all, nSMases of mammalian and
bacterial origin. The Mg2þ e¡ect on these enzymes becomes
saturated at ca. 1033 M. The role of Mg2þ in the activation of
B. cereus SMase was analyzed in detail by Fujii et al. [58]. The
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enzyme had two classes of binding sites for Mg2þ, with bind-
ing constants 2.1U102 and 5.0U106 M31 at pH 6.0. The high-
a⁄nity site was saturated with a single Mg2þ ion. The func-
tional meaning of the high-a⁄nity binding is unclear. Low-
a⁄nity Mg2þ binding was essential for catalysis, but unrelated
to substrate binding. Mg2þ binding also protected the enzyme
against alkaline denaturation.
2.2.2. Binding of substrate. As with all other lipases, sub-
strate binding is only one part of a more complex phenome-
non, involving surface adsorption and perhaps other precata-
lytic stages. The interaction of SMase with its substrate has
been carefully studied by Fanani and Maggio [72] using sphin-
gomyelin monolayers at an air^water interface. The enzyme
(B. cereus) was injected into the aqueous phase, from which it
could interact with the substrate. Three stages could be dis-
tinguished in the enzyme activity, (i) a latency period, during
which interfacial adsorption and other precatalytic steps took
place, (ii) a period of steady-state enzyme activity, i.e. a con-
stant rate of substrate degradation (pseudo zero-order ki-
netics), and (iii) a period of gradual halting of product for-
mation.
During the latency period the amount of SMase adsorbed
onto the lipid monolayer increased up to a plateau, the latter
marking the start of the constant velocity region. The amount
of adsorbed enzyme did not vary with the presence of prod-
uct. An interface/subphase partition coe⁄cient KP = 7U1034
was calculated for the enzyme, indicating a high tendency of
SMase to associate with the lipid interface. Enzyme partition
to the interface and interfacial activation were essentially ir-
reversible.
Fanani and Maggio [72] analyzed quantitatively the activa-
tion phase of the SMase reaction, and compared the exper-
imental results with six di¡erent kinetic models. The best ¢t
was found for the so-called model V, whose kinetic scheme is
as follows:
2E3
Kp
2Ei þ 2S3
K
2EiS3
Kd ðEiSÞ2!kact ðEi SÞ2 þ S3
KS ðEi SÞ2S
!kact ðEi SÞ2 þ P
After the partition step the model involves association of the
enzyme with the substrate and subsequent dimerization before
activation. The proportion of activated enzyme (Ei*) was as-
sumed to be very small in relation to the total amount of
enzyme at the interface (Ei+Ei*). Enzyme activation was the
rate-limiting step for the reaction. The kinetics of activation
was slow (kact = 3U1033 s31) as compared to the rate of ca-
talysis in the steady-state regime (kcat = 4U102 s31), the latter
estimated on the basis of classic Michaelis^Menten analysis.
The authors conclude that the lag time observed in SMase
catalysis is the result of an equilibrium between monomolec-
ular and bimolecular activated states of the enzyme in the
interface, and of a slow activation process.
2.2.3. Mechanism of catalysis. A model for the interaction
of SMase with sphingomyelin (Fig. 1) and a catalytic mecha-
nism (Fig. 2) have been proposed for B. cereus SMase respec-
tively by Matsuo et al. [63] and by Fujii et al. [58], on the
basis of four lines of evidence: (i) mutational analysis suggest-
ing that Asp 126 and Asp 156 are involved in substrate rec-
ognition, and that Asp 295, His 151 and His 296 are essential
for the hydrolytic activity [73]. Note that His 136 and His 272
are essential for the activity of nSMase 1 [49,50]. His 134 and
His 252 of DNase correspond to histidines 136 and 272 of
nSMase 1, and to histidines 151 and 296 of B. cereus SMase.
(ii) The prediction by Matsuo et al. [63] of the three-dimen-
sional structure of the enzyme using a protein fold recognition
method, which suggested that SMase adopts a structure sim-
ilar to that of bovine pancreatic DNase I. This prediction
included the proposal of several amino acid residues involved
in catalysis and enzyme recognition, in agreement with the
results of mutational analysis. (iii) The suggestion by Weston
et al. [74], on the basis of their X-ray studies of a DNase I^
substrate complex, that His 252 of DNase I acts as a general
base to accept a proton from a water molecule, which then, as
a nucleophile, attacks the phosphoryl group, and His 134
functions as a general acid to protonate the leaving oxygen
of the phosphoester. His 252 and His 134 from DNase I
correspond to His 296 and His 151, respectively, in B. cereus
SMase. (iv) The studies by Fujii et al. [58] on the pH depen-
dence of kinetic parameters of the enzyme. Fujii et al. [58]
conclude that the mechanism of SMase appears to be one
of general-base catalysis, with His 296 acting as a general
base (Fig. 2).
2.3. Sphingomyelinase assay
Two di¡erent situations must be distinguished, (i) assays of
pure enzyme and (ii) assays of cell extracts. When puri¢ed
enzyme preparations are available, no labeled substrate is re-
quired. Natural or synthetic sphingomyelin is prepared, pure
or mixed with other lipids, in the form of extruded large
unilamellar vesicles (LUV) ca. 100 nm in diameter [75].
When pure sphingomyelin vesicles are used extrusion must
take place at a temperature close to or above the gel^£uid
transition temperature of the lipid, i.e. often in the 45^50‡C
range. LUV and enzyme are mixed in the appropriate assay
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Fig. 1. A model for the interaction between SMase and sphingo-
myelin. These residues are all conserved in homologous bacterial
SMases. Residues W28, E53, F55, N130, Q153, W232 and D295
may be involved in substrate recognition. E53 and D295 would be
involved in hydrolysis of the phosphodiester bond. M2þ denotes the
metal ion that is essential for catalysis. Redrawn from [63].
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Fig. 2. A general-base catalytic mechanism for bacterial sphingo-
myelinase. Redrawn from [58].
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bu¡er and aliquots are removed at ¢xed time intervals. The
aliquots are mixed with chloroform^methanol and, after
phase separation, phosphorus (from phosphorylcholine) is as-
sayed in the aqueous phase. A detailed description of the
procedure can be found in Ruiz-Argu«ello et al. [76].
When LUV are assayed with sphingomyelinase, ceramide
production in the bilayers leads to vesicle aggregation, which
in turn produces an increase in turbidity or light scattering in
the suspension. Thus the reaction can be followed in real time
just by measuring the increase in turbidity (absorbance at 500
nm) or in light scattering (e.g. with a £uorometer with both
the excitation and emission monochromators adjusted at 500
nm). The chemical assay of the water-soluble product phos-
phorylcholine and the turbidity assay give superimposable re-
sults [76,77].
In some commercial preparations of puri¢ed sphingomyeli-
nase from B. cereus a contamination by phospholipase C may
occur. This is irrelevant when the substrate consists of pure
sphingomyelin. But when the LUV contain glycerophospho-
lipids, e.g. phosphatidylcholine, the contamination poses a
serious problem, because both enzymes will be giving o¡ the
same water-soluble end-product phosphorylcholine. When
this is the case, the assays must be performed in the presence
of o-phenanthroline, a speci¢c inhibitor of phospholipase C
that is innocuous for SMase [77^79].
Assaying SMase activity in cell extracts requires that sphin-
gomyelin be labeled, radioactively, £uorescently or otherwise.
Also, and because of the di⁄culty in bringing together the
enzyme and substrate molecules in the presence of cell homo-
genates, the assays are often carried out in Triton X-100 or
other suitable detergents. It should be noted that, apart from
emulsifying the substrate, the detergents bind and modify the
enzyme activity, thus they are better avoided whenever possi-
ble. If their use is required, detergent concentration and initial
detergent:substrate ratio must be kept constant for reproduc-
ibility of assays. After catalysis has taken place, the labeled
enzyme products are separated, most often by thin-layer chro-
matography, and quantitated. A general description of SMase
assays in cell extracts has been provided by Santana et al. [80],
and by Gatt [81]. Samet and Barenholz [14] describe in detail
assay conditions for aSMase and nSMase using a £uorescent
sphingomyelin derivative. An alternative £uorescence assay is
given by Loidl et al. [82]. Liu and Hannun [83] provide a
detailed description of a SMase assay using a radioactively
labelled substrate, namely N-[methyl-14C]sphingomyelin. A
novel non-radioactive approach is presented by Zhou et al.
[84] who use biotinylated substrate conjugates. Then they pu-
rify the enzyme products by bioa⁄nity capture on strepta-
vidin-agarose beads and, after release, they analyze them by
electrospray ionization mass spectroscopy. High-throughput
methods for sphingomyelinase screening, using N-[methyl-
14C]sphingomyelin, have also been published [85,86].
A SMase assay kit is commercially available, based on the
use of 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red), a
sensitive £uorogenic probe for H2O2. First, SMase hydrolyzes
the sphingomyelin to yield ceramide and phosphorylcholine.
After the action of alkaline phosphatase, which hydrolyzes
phosphorylcholine, choline is oxidized by choline oxidase to
betaine and H2O2. Finally, H2O2, in the presence of a peroxi-
dase, reacts with Amplex red to generate a highly £uorescent
product. However, it should be noted that any enzyme gen-
erating phosphorylcholine will give o¡ the £uorescent prod-
uct, thus the assay does not discriminate SMase from phos-
pholipase C.
2.4. Sphingomyelinase inhibitors
Some physiological SMase inhibitors, e.g. glutathione, have
been mentioned in Section 2.1. Among the pharmacological
inhibitors scyphostatin, obtained from mycelial extracts from
the discomycete Trichopeziza mollissima is becoming widely
accepted as a neutral sphingomyelinase inhibitor [37,42,87^
89]. Other natural inhibitors of mammalian nSMase include
macquarimicin A [90], alutenusin [91], chorogentisylquinone
[92], and manumycin A [93]. Some synthetic substrate ana-
logues can also be used as SMase inhibitors, e.g. a sphingo-
myelin methylene analogue [94], or a di£uoromethylene ana-
logue [95]. Arenz and Giannis [96] have produced the ¢rst
synthetic irreversible inhibitor of nSMase.
Inhibitors of aSMase are also known, such as the xanthone
K-mangostin, isolated from the bark of Garcinia speciosa [97].
K-Mangostin has recently been obtained by organic synthesis
[98].
3. Sphingomyelinase^membrane interactions
At least two obvious aspects must be considered in this
section, namely the in£uence of the membrane lipids on sphin-
gomyelinase activity, and the e¡ects of the enzyme on the
membrane properties. Among the latter, we shall deal sepa-
rately with enzyme e¡ects on membrane permeability, and
e¡ects on membrane architecture.
3.1. Lipid e¡ects on sphingomyelinase activity
The studies on this subject are scarce, particularly for sub-
strates in bilayer form. Linke et al. [99] have recently pub-
lished data that show stimulation of recombinant human acid
sphingomyelinase by lipids that occur frequently in lysosomes.
The substrate was present in the form of liposomes, and no
detergents were used. Liposomes contained basically phospha-
tidylcholine, cholesterol and sphingomyelin. To this mixture
other lipids were added as required. Lysosomally occurring
lipids, e.g. phosphatidylinositol and bis-(monoacylglycero)-
phosphate, were e¡ective stimulators (by up to three-fold) of
aSMase activity. Dolichol, and in particular dolicholphos-
phate, which occur in both Golgi and lysosomal membranes,
were also e¡ective aSMase activators. Interestingly, Linke et
al. [99] also studied the e¡ect of membrane curvature on
aSMase activity, by preparing unilamellar liposomes of vary-
ing diameters, in the sub-50 to 200 nm range. Enzyme activity
increased remarkably with increasing curvature (decreasing
size) of the vesicles. However, it should be noted that, in
the smaller liposomes tested, the vesicles are subjected to a
considerable lateral tension, which could by itself have an
in£uence on enzyme activity. Finally, Linke et al. [99] were
able to demonstrate, using surface plasmon resonance, that
binding of a SMase to lipid bilayers was actually increased
by anionic lipids such as bis-(monoacylglycero)phosphate.
In another recent paper, Ruiz-Argu«ello et al. [100] have
noted the unusual fact that most molecular species of sphin-
gomyelin are in the gel state in the physiological range of
temperatures, i.e. most naturally occurring sphingomyelins
have gel-to-£uid transition temperatures in the 35^45‡C range.
These authors used liposomes (LUV) composed of pure egg
sphingomyelin (gel-to-£uid transition temperature ca. 39‡C)
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or of binary mixtures of sphingomyelin and glycerophospho-
lipids (phosphatidylcholine or phosphatidylethanolamine).
The enzyme was of bacterial (B. cereus) origin. SMase was
active on pure sphingomyelin bilayers but activity was exceed-
ingly low when the lipid was in the gel state. It increased by
over one order of magnitude when the substrate went from
the gel to the £uid phase. SMase activity was found to exhibit
lag times, followed by bursts of activity. Lag times decreased
markedly when the substrate went across the phase transition
to the £uid state. When egg phosphatidylcholine, or egg phos-
phatidylethanolamine was included in the bilayer composition
together with sphingomyelin, sphingomyelinase activity at
37‡C, which was negligible for the pure sphingolipid bilayers,
was seen to increase with the proportion of glycerophospho-
lipid, while the latency times became progressively shorter. A
di¡erential scanning calorimetry study of the mixed-lipid
vesicles revealed that both phosphatidylcholine and phospha-
tidylethanolamine decreased in a dose-dependent way the
transition temperature of sphingomyelin. Thus, as those glyc-
erophospholipids were added to the membrane composition,
the proportion of sphingomyelin in the £uid state at 37‡C
increased accordingly, in this way becoming amenable to rap-
id hydrolysis by the enzyme. Thus sphingomyelinase requires
the substrate in bilayer form to be in the £uid state, irrespec-
tive of whether this is achieved through a thermotropic tran-
sition or by modulating bilayer composition.
Also relevant in this context is the observation by Ja¡rezou
et al. [101] that ceramide enhances neutral sphingomyelinase
activity in myeloid leukemia cells and in normal skin ¢bro-
blasts. However, these results were obtained with short-chain,
cell-permeant ceramides, whose physical e¡ects on membranes
may be di¡erent from the more frequent long-chain ones [9].
The subject is interesting enough to deserve a more detailed
investigation.
3.2. E¡ects of sphingomyelinase activity on membrane
properties
3.2.1. E¡ects on membrane permeability. Ruiz-Argu«ello et
al. [76] were the ¢rst to point out that generation of ceramides
in the bilayer induced e¥ux of vesicle or cell contents. They
treated either LUV consisting of sphingomyelin, phosphati-
dylethanolamine and cholesterol (at a 2:1:1 molar ratio), or
resealed erythrocyte ghosts, both loaded with low molecular
mass £uorescent dyes, with bacterial SMase. In both cases,
rapid e¥ux ensued in parallel with enzyme activity. This
was in contrast to the situation of phosphatidylcholine:phos-
phatidylethanolamine:cholesterol (2:1:1) vesicles treated with
phospholipase C, in which case no release of aqueous contents
was observed.
The subject has been explored in more detail by Montes et
al. [102]. They entrapped in liposomes £uorescent solutes of
varying sizes, up to 20 kDa, and complemented the experi-
ments in which ceramide was generated by SMase, with others
in which ceramide was added in organic solvent to the pre-
formed liposome suspension. Small proportions of ceramide
(10 mol% of total lipid) that may exist under physiological
conditions of ceramide-dependent signalling were used. When
long-chain (egg-derived) ceramides were used, both externally
added and enzymatically produced ceramides induced release
of vesicle contents. However, the same proportion of ceram-
ides generated by SMase induced faster and more extensive
e¥ux than when added in organic solution to the vesicles.
Remarkably, SMase treatment of bilayers containing 50
mol% sphingomyelin gave rise to release of £uorescein-deriv-
atized dextrans of molecular mass V20 kDa, i.e. larger than
cytochrome c. Furthermore, some experiments in the same
paper were designed to explore the mechanism of ceramide-
induced e¥ux. Two properties of ceramide appear to be im-
portant in the process of membrane restructuring that leads to
solute e¥ux. One is the capacity of ceramide to induce a
‘negative’ monolayer curvature, i.e. a curvature of the oppo-
site sign to that found in the outer monolayer of cell mem-
branes [9]. The other is its tendency to segregate into ceram-
ide-rich domains [103]. The interface between ceramide-rich
and -poor domains is probably the high-e¥ux region (Fig.
3). Very recently Siskind et al. [104] have shown that ceramide
increases the permeability of the mitochondrial outer mem-
brane to proteins of molecular mass up to 60 kDa.
3.2.2. E¡ects on membrane aggregation and fusion. Pre-
vious studies from this laboratory ([105] ; review in [106])
had shown that phospholipase C induced aggregation and
fusion of vesicles composed of phosphatidylcholine, phos-
phatidylethanolamine and cholesterol, in a 2:1:1 molar ratio.
Interestingly, bacterial SMase acting on vesicles containing
sphingomyelin, phosphatidylethanolamine and cholesterol
(2:1:1 molar ratio) produced (apart from solute e¥ux, as
discussed above) vesicle aggregation, but not fusion, the latter
being de¢ned as intervesicular mixing of lipids and of aque-
ous contents. However, when the sphingomyelin-containing
vesicles were treated with low amounts of SMase, so that
the rate of sphingomyelin hydrolysis was reduced considerably
[107], as compared to that of the previously discussed experi-
ments, a situation was found in which about one third of the
vesicles were clearly larger in size (by ca. six-fold) than the
original ones. Fusion had taken place together with extensive
leakage, and because of this and other reasons, it is possible
that SMase-induced fusion occurs via a di¡erent mechanism
than phospholipase C-induced fusion [106,107].
Other lines of evidence concur in pointing towards a fuso-
genic capacity of SMase. Holopainen et al. [108] showed mi-
croscopic images of ‘endocytic’ budding of vesicles composed
of phosphatidylcholine and sphingomyelin, upon addition of
sphingomyelinase. Budding and ¢ssion are probably mirror
image processes of fusion, and they may share the same
kind of intermediates. Holopainen et al. [108] attributed the
observed budding to the tendency of ceramide to separate into
domains, and to its negative spontaneous curvature that
would lead to membrane invagination (Fig. 3).
Also relevant is the observation by Zha et al. [109] that
endocytotic vesicles are formed in the absence of ATP when
¢broblasts and macrophages are treated with exogenous
SMase (or ceramides). According to those authors, addition
of B. cereus SMase to ATP-depleted cells induces the rapid
formation of vesicles, approximately 400 nm in diameter, not
enriched in clathrin or caveolin, that pinch o¡ from the plas-
ma membrane and go into the cytosol. Zha et al. [109] spec-
ulate that hydrolysis of sphingomyelin in the plasma mem-
brane causes inward curvature and subsequent formation of
sealed vesicles, in agreement with the biophysical data [106].
Moreover, entry of Neisseria gonorrhoeae into non-phagocytic
cells is mediated by the activation of an acidic sphingomyeli-
nase [110], while SMases in the genus Listeria mediate bacte-
rial escape from phagocytic vacuoles and cell-to-cell propaga-
tion [60,70]. These examples of bacterial movements across
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membranes require either true membrane fusion or events
mechanistically related to fusion, all of them induced by a
SMase. In a non-membranous system, SMase was seen to
induce aggregation and fusion of LDL particles [111]. In
turn, the modi¢ed LDL particles bound the human aortic
proteoglycans with increased strength.
Coming back to studies in model membranes, Ruiz-Argu«el-
lo et al. [79] were able to observe the cooperative action of
ceramide and diacylglycerol, generated in situ respectively by
SMase and phospholipase C, to induce aggregation and fu-
sion of vesicles containing equimolar mixtures of sphingomye-
lin, phosphatidylcholine, phosphatidylethanolamine, and cho-
lesterol. Neither enzyme was able to produce aggregation or
fusion on its own under those conditions, but when both
enzymes were added together their activities appeared to be
mutually potentiated. In a conceptually related study, carried
out on lipid monolayers at the air^water interface, Fanani and
Maggio [112] demonstrated that the activities of SMase and
phospholipase A2 could be mutually modulated. The activity
of one enzyme was a¡ected by its own reaction products and
by substrates and products of the other enzyme. These au-
thors concluded that the mutual lipid-mediated interfacial
modulation between both phosphohydrolytic pathways indi-
cated that phospholipid degradation might be self-ampli¢ed
or dampened depending on subtle changes of surface pressure
and composition.
4. Concluding remarks. The ‘To Do’ list
In the nearly 40 years elapsed since the ¢rst descriptions of
sphingomyelinases, and particularly in the last decade, enor-
mous progress has been made. Several animal and bacterial
SMases have been cloned and overexpressed in a variety of
cells, a mechanism of action has been proposed and tested
with good results, and the process of interfacial activation is
understood to a reasonable extent. Most importantly, SMases
have been related to cell processes (apoptosis, cell prolifera-
tion, cell di¡erentiation, membrane fusion/¢ssion) that go well
beyond their originally proposed role in the intermediary me-
tabolism of lipids. Moreover, biophysical studies on model
membranes have provided plausible explanations for the phys-
iological e¡ects of these enzymes. However, a number of im-
portant questions remain still (and pressingly) unanswered, we
shall close this review by listing a few of them. (i) The topol-
ogy of eukaryotic SMases, and, in particular, their possible
changes in location between the resting and activated states.
(ii) Cloning of mammalian neutral SMases: are the cloned
proteins the physiological neutral SMases in the cell? (iii)
The relationship between SMases, cholesterol homeostasis,
and atherogenesis. (iv) The phylogeny of the known mamma-
lian SMases. What are the SMases in non-mammalian cells?
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Fig. 3. A schematic drawing of the e¡ects of SMase on lipid bilayers. In a bilayer containing both sphingomyelin and glycerophospholipids,
sphingomyelin will be in the £uid state [100]. After SMase action, ceramides are still mixed with the glycerophospholipids, but the bilayer is in
a metastable state. Even if SMase is acting only on one side of the bilayer, ceramide £ip-£op tends to distribute ceramide molecules more or
less evenly across the bilayer [79,106]. Simultaneously, and perhaps competing with £ip-£op, lateral segregation forms patches of solid ordered
ceramide-rich phases. The outcome of these events is the increased membrane e¥ux through the solid^£uid interface [76,102] and/or the bending
of the bilayer, perhaps contributing to the formation of fusion/¢ssion intermediates of the ‘stalk’ type [79,106].
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